|
Sub-category:
Lymphoma
Category:
Lymphoma and Plasma Cell Disorders
Meeting:
2009 ASCO Annual Meeting
Session Type and Session Title:
This abstract will not be presented at the 2009 ASCO Annual Meeting but has been published in conjunction with the meeting.
Abstract No:
e19514
Citation:
J Clin Oncol 27, 2009 (suppl; abstr e19514)
Author(s):
K. Schwartz, Advisors to Patients Against Lymphoma; Patients Against Lymphoma, Riegelsville, PA
Abstract:
Background: There is an increasing number of investigational agents for lymphomas and a limited patient pool, approximately 5% of available patients. Thus, identifying and addressing obstacles to study enrollment is vital to making progress. Methods: This analysis was made from a non-random population of 251 lymphoma patients with online access to our survey. Results: In this cohort, 43% reported High Interest in clinical trials, 50% have Considered Trials, and 27% Have Participated. Patients who considered studies (126) ranked the following reasons for declining as significant: Randomization (70), Insurance (49), Study Risks / Toxicities (42), Travel and Lodging (30), Eligibility (28), Tests and Procedures (12), and a perception that Regular Treatment is superior (6). See Table 1 for associations with consideration of clinical trials and participation. Conclusions: In this cohort, interest in clinical trials and participation rates were much higher than generally cited. As expected, the discussion of clinical trials with the patient's oncologist was associated with the highest consideration (85%) and participation (53%) rates, suggesting a need to increase awareness of study protocols among treating physicians so that this discussion can become more routine. Patient issues and perceptions regarding randomization, study risk, eligibility, and tests and procedures suggest an opportunity to improve enrollment in clinical trials by focusing on these aspects of study design, specifically, attending to the rationale of the protocol as a treatment decision.
| | Survey Participants (n = 251) | Overall | Considered Trial | Have Participated |
| | Oncologist Discussed Trial | 112 (45%) | 95 (85%) | 59 (53%) | | Oncologist is Specialist | 141 (56%) | 75 (53%) | 44 (31%) | | Oncologist is Investigator | 96 (38%) | 66 (69%) | 42 (44%) | | Pt had 2nd Opinion | 168 (67%) | 107 (64%) | 60 (36%) | | Pt had 2nd Pathology Eval | 152 (61%) | 91 (60%) | 51 (34%) | | Overall | 251 | 126 (50%) | 67 (27%) |
| | Associations with consideration of clinical trials and participation |
Abstract Disclosures
Faculty and Discussant Disclosures
Annual Meeting Planning Committee Disclosures
2009 Annual Meeting Proceedings Part I Errata
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy
and are designated with a caret symbol (^) here and in the print version.
 Associated Presentation(s):
Other Abstracts in this Sub-Category:
Abstracts by K. Schwartz:
Presentations by K. Schwartz:
Educational Book Manuscripts by K. Schwartz:
|
